Perjeta (pertuzumab) / Roche 
Welcome,         Profile    Billing    Logout  

248 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Perjeta (pertuzumab) / Roche
NCT04929548: Exploratory Study of Neoadjuvant Treatment of HER2-positive Breast Cancer With Py in Combination With HP

Not yet recruiting
4
20
NA
Pyrotinib Maleate Tablets
Wuhan University
Breast Cancer
01/22
09/27
NeoON, NCT05036005: Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label

Recruiting
4
108
Europe
Ontruzant, SB3, Chemotherapy, Pertuzumab
Institut fuer Frauengesundheit, Samsung Bioepis Co., Ltd.
Breast Cancer, Breast Neoplasms, Breast Cancer Female, HER2-positive Breast Cancer
04/23
07/23
2023-000156-38: Health economic analysis of pertuzumab and trastuzumab for metastatic breast cancer

Not yet recruiting
4
90
Europe
pertuzumab, trastuzumab, pertuzumab, trastuzumab, Solution for injection, Solution for infusion, Powder for concentrate for solution for infusion, Phesgo 600/600, Perjeta, Herzuma
Semmelweis University, Department of Internal Medicine and Oncology, Semmelweis University, Roche Magyarország Kft.
HER-2 positive advanced breast cancer, locally unresectable or metastatic breast cancer, Metastatic, advanced breast cancer, Diseases [C] - Cancer [C04]
 
 
NCT06578299: Inetetamab Combined With Paclitaxel With/Without Pertuzumab for Previously Treated HER2-positive Advanced Breast Cancer

Not yet recruiting
4
100
NA
Inetetamab and Paclitaxel ± Pertuzumab
Fudan University
Breast Cancer Stage IV
03/26
08/27
neo-ECOH study, ChiCTR2100041951: Efficacy and cardiac safety in the neoadjuvant treatment of stage II-III HER2- positive breast cancer with Docetaxel, Carboplatin, Pertuzumab and HLX02: a single-arm study

Recruiting
4
200
 
TCbHP
Guangdong Provincial Hospital of Chinese Medicine; Guangdong Provincial Hospital of Chinese Medicine, Horizontal project funding
Breast Cancer
 
 
DISCORDANT, NCT06585969: A Randomised Trial Comparing Molecular Guided Treatment to Physician's Choice in Discordant ER-positive/HER2-negative Metastatic Breast Cancer

Not yet recruiting
4
250
NA
Treatment strategy
Danish Breast Cancer Cooperative Group
Metastatic Breast Cancer, ER-positive Breast Cancer, Basal Li
05/29
05/29
ChiCTR2000032568: Real World Study on the Efficacy and Safety of Trastuzumab Combined With Delayed Pertuzumab Application in the Treatment of HER2 Positive Breast Cancer: an Observational, Non-Interventional, Prospective Study

Recruiting
4
746
 
Only used Trastuzumab ;Trastuzumab combined with delayed Pertuzumab
Guangdong Provincinal Hospital of Traditional Chinese Medicine; Guangdong Provincinal Hospital of Traditional Chinese Medicine, self-raised
Breast Cancer
 
 
ChiCTR2400079934: A multicenter, prospective, non-inferiority clinical research of taxanes combined with pyrrotinib +/- trastuzumab versus taxanes combined with trastuzumab and pertuzumab neoadjuvant therapy for HER2-positive early or locally advanced breast cancer

Recruiting
4
582
 
Pyrotinib combined with taxanes; Trastuzumab plus pyrotinib and taxane; Trastuzumab plus pertuzumab and taxane
The First Peolple's Hospital of Foshan; The First Peolple's Hospital of Foshan, None
Breast cancer
 
 
NCT05420454: A Study for the Neoadjuvant Treatment of Breast Cancer

Recruiting
4
1576
RoW
Docetaxel, Carboplatin, Trastuzumab, Pertuzumab, Nab paclitaxel, Epirubicin, Cyclophosphamide
Second Affiliated Hospital, School of Medicine, Zhejiang University
Breast Cancer
06/27
12/27
NCT05420467: A Study for the Adjuvant Treatment of Breast Cancer

Recruiting
4
2413
RoW
Docetaxel, Carboplatin, Trastuzumab, Pertuzumab, Nab paclitaxel, Epirubicin, Cyclophosphamide
Second Affiliated Hospital, School of Medicine, Zhejiang University
Breast Cancer
07/27
12/27
ChiCTR2100052429: Neoadjuvant pegylated liposomal doxorubicin in patient with HER-2 positive breast cancer : a prospective real-world clinical study

Not yet recruiting
4
450
 
Doxorubicin hydrochioride liposome injection plus cyclophosphamide followed by docetaxel plus trastuzumab and pertuzumab ;Docetaxel plus carboplatin combined with trastuzumab and pertuzumab
Liaoning Cancer Hospital; Liaoning Cancer Hospital, CSPC Ouyi Pharmaceutical Co., Ltd.
Breast cancer
 
 
HERB TEA, UMIN000030783: A phase III study comparing T-DM1 with pertuzumab, trastuzumab and docetaxel in elderly patients with advanced stage HER2 positive breast cancer (JCOG1607, study)

Active, not recruiting
3
330
Japan
Herceptin (trastuzumab) - Roche, Perjeta (pertuzumab) - Roche, docetaxel - Generic mfg.
National Cancer Center Hospital
HER2 positive advanced breast cancer
 
 
SHR-A1811-307, CTR20232893: A multicenter, randomized, open-label, positive-controlled phase III clinical study of SHR-A1811 for injection with or without pertuzumab versus trastuzumab, pertuzumab and docetaxel in HER2-positive recurrent or metastatic breast cancer

Ongoing
3
866
China
trastuzumab rezetecan (SHR-A1811) - Jiangsu Hengrui Pharma, Perjeta (pertuzumab) - Roche, Herceptin (trastuzumab) - Roche, docetaxel - Generic mfg.
Suzhou Shengdia Biopharmaceutical Co., Ltd
HER2-positive recurrent or metastatic breast cancer
 
 
2013-001863-21: Optimizing neoadjuvant systemic treatment in HER2 positive breast cancer - the TRAIN-2 study

Ongoing
3
394
Europe
Herceptin, Carboplatine Sandoz, Taxol, Endoxan, 5-Fluorouracil Sandoz, Epirubicine HCl Sandoz, Perjeta, Concentrate for solution for infusion, Powder for solution for infusion, Solution for infusion, Herceptin, Carboplatine Sandoz, Taxol, Endoxan, 5-Fluorouracil Sandoz, Epirubicine HCl Sandoz, Perjeta
BOOG Study Center, Roche
Breast cancer, HER2 positive, stage II or III, Breast cancer, Diseases [C] - Cancer [C04]
 
 
NCT02003209: Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

Active, not recruiting
3
315
US
Aromatase Inhibition Therapy, Aromatase Inhibition, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cytology Specimen Collection Procedure, Cytologic Sampling, Docetaxel, Docecad, RP 56976, RP-56976, RP56976, Taxotere, Taxotere Injection Concentrate, Goserelin Acetate, ZDX, Zoladex, Laboratory Biomarker Analysis, Pertuzumab, 2C4, 2C4 Antibody, BCD-178, EG1206A, HLX11, HS627, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, Pertuzumab Biosimilar BCD-178, Pertuzumab Biosimilar EG1206A, Pertuzumab Biosimilar HLX11, Pertuzumab Biosimilar HS627, Pertuzumab Biosimilar TQB2440, Rhumab 2C4, rhuMAb2C4, RO4368451, TQB 2440, TQB-2440, TQB2440, Quality-of-Life Assessment, Quality of Life Assessment, Therapeutic Conventional Surgery, Trastuzumab, ABP 980, ALT02, Biceltis, CANMab, CT-P06, CT-P6, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Hercessi, Herclon, Hertraz, Herwenda, Herzuma, Kanjinti, Ogivri, Ontruzant, PF-05280014, QL 1701, QL-1701, QL1701, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, Trastuzumab Biosimilar CT-P6, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar QL1701, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-herw, Trastuzumab-pkrb, Trastuzumab-qyyp, Trastuzumab-strf, Trastuzumab-zerc, Trazimera, Zercepac, Whole Breast Irradiation
National Cancer Institute (NCI), NRG Oncology
HER2-Positive Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
10/16
12/24
APHINITY, NCT01358877 / 2010-022902-41: A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer

Checkmark APHINITY trial of Perjeta + Herceptin in adjuvant HER2-positive breast cancer
Nov 2019 - Nov 2019: APHINITY trial of Perjeta + Herceptin in adjuvant HER2-positive breast cancer
Checkmark APHINITY trial in adjuvant HER2+ breast cancer at ASCO 2017
Jun 2017 - Jun 2017: APHINITY trial in adjuvant HER2+ breast cancer at ASCO 2017
Checkmark APHINITY trial of Perjeta + Herceptin in adjuvant HER2-positive breast cancer
More
Active, not recruiting
3
4804
Europe, Canada, Japan, US, RoW
5-Fluorouracil, Carboplatin, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin, Paclitaxel, Pertuzumab, Perjeta®, Placebo, Trastuzumab, Herceptin®
Hoffmann-La Roche, Genentech, Inc., Breast International Group
Breast Cancer
12/16
11/24
TRAIN-2, NCT01996267: Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer,

Active, not recruiting
3
437
Europe
PTC+Pertuzumab, Paclitaxel; 80 mg/m2; day 1,8, Trastuzumab; 6 mg/kg (loading dose 8 mg/kg); day 1, Carboplatin; AUC=6; day 1, Pertuzumab; 420 mg (loading dose 840 mg); day 1, FEC-T+Pertuzumab, Fluorouracil; 500 mg/m2; day 1, Epirubicine; 90 mg/m2; day 1, Cyclophosphamide 500 mg/m2; day 1, Trastuzumab; 6 mg/kg (loading dose 8 mg/kg)
The Netherlands Cancer Institute, Roche Pharma AG, Borstkanker Onderzoek Groep
Breast Cancer, HER2 Positive
12/18
12/30
IMpassion050, NCT03726879 / 2018-001881-40: A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer

Hourglass Jan 2021 - Dec 2021 : From Impassion050 trial in combination with doxorubicin, cyclophosphamide followed by paclitaxel, trastuzumab and pertuzumab in early HER2+ breast cancer
Checkmark From IMpassion050 trial for neoadjuvant HER2-positive breast cancer
Jun 2021 - Jun 2021: From IMpassion050 trial for neoadjuvant HER2-positive breast cancer
Completed
3
454
Europe, Canada, Japan, US, RoW
Atezolizumab, Tecentriq, Placebo, Doxorubicin, Adriamycin, Cyclophosphamide, Cytoxan, Neosar, Paclitaxel, Taxol, Trastuzumab, Herceptin, Pertuzumab, Perjeta, Trastuzumab Emtansine, Kadcyla
Hoffmann-La Roche, Chugai Pharmaceutical
Breast Cancer
02/21
08/23
PANSY, NCT04193059: Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer

Recruiting
3
1560
RoW
Paclitaxel, Carboplatin, Epirubicin, Cyclophosphamide, Trastuzumab, Pertuzumab, Docetaxel
Fudan University
Breast Cancer
07/21
07/24
2021-000603-21: DESTINY-Breast11 will compare trastuzumab deruxtecan (T-DXd) alone or in sequence with other medications, known as THP, with standard of care treatment (ddAC-THP) and determine its safety and efficacy in patients with HER2-positive early breast cancer. Lo studio DESTINY-Breast11 confronterà trastuzumab deruxtecan (T-DXd) usato singolarmente o in sequenza con altri farmaci noti come THP, con la terapia standard ddAC-THP) e determinerà la sua sicurezza ed efficacia in pazienti con carcinoma mammario HER2-positivo in stadio precoce.

Not yet recruiting
3
900
Europe, RoW
Paclitaxel, Trastuzumab Deruxtecan, Pertuzumab, Doxorubicin, Trastuzumab, Doxorubicina, Ciclofosfamide, Non applicabile, non applicabile, [na], [DS8201a], [Non applicabile], [non applicabile], Concentrate for solution for injection/infusion, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Powder for solution for injection/infusion, Solution for infusion, Tablet, Bentadax, Paclitaxel Amneal 6mg/ml Concentrate for Solution for Infusion, Paclitaxel 6 mg/ml Concentrate for Solution for Infusion, perjeta, Doxorubicin Hydrochloride Bendalis 2mg/ml Solution for Injection, Ontruzant, Doxorubicin Teva 2mg/ml Concentration for solution for infusion, Endoxan, Trazimera, Paclitaxel Hospira 6mg/ml Concentrate for Solution for Infusion, Herzuma, Kanjinti, Doxorubicin Hydrochloride (Adrimedac) 2mg/ml Solution for Infusion
ASTRAZENECA AB, AstraZeneca AB, AstraZeneca AB
Early stage HER2-positive breast cancer (T stage >= T3, lymph node positive, or inflammatory) Carcinoma mammario HER2-positivo in stadio precoce (stadio T stage >= T3, linfonodo positivo o infiammatorio), Early breast cancer Carcinoma mammario in stadio precoce, Diseases [C] - Cancer [C04]
 
 
NCT04514419: Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel

Recruiting
3
408
RoW
HS627, Trastuzumab + HS627 + Docetaxel, Pertuzumab, Trastuzumab Pertuzumab Docetaxel
Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd
Breast Cancer
11/21
11/21
BOLD-1, NCT02625441 / 2015-002323-25: Adjuvant Trastuzumab, Pertuzumab Plus Docetaxel in the Treatment of Early HER2-positive Breast Cancer

Active, not recruiting
3
516
Europe
Pertuzumab, Perjeta, Trastuzumab, Herceptin
Helsinki University Central Hospital
Breast Cancer
12/21
06/25
NCT04665986: Neoadjuvant Study of Navelbine in Patients With HER2 Positive Breast Cancer

Not yet recruiting
3
50
NA
Navelbine, Docetaxel
Zhejiang Cancer Hospital
Breast Cancer
02/22
02/23
EMERALD, NCT03264547: A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab

Recruiting
3
480
Japan
Pertuzumab, Perjeta, Trastuzumab, Herceptin, Docetaxel, Taxotere, Paclitaxel, Taxol, Eribulin, Halaven
Japan Breast Cancer Research Group, Eisai Co., Ltd.
Breast Cancer
04/22
10/23
NCT04629846: Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.

Completed
3
517
RoW
Trastuzumab, Herceptin®, QL1209, Recombinant anti-HER-2 domain Ⅱ humanized monoclonal antibody injection, Pertuzumab, Perjeta®, Docetaxel, Docetaxel injection, surgery
Qilu Pharmaceutical Co., Ltd.
Breast Cancer
08/22
10/23
TQB2440-III-01, NCT05985187: Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.

Active, not recruiting
3
412
RoW
TQB2440 injection + Trastuzumab + Docetaxel, Perjeta + Trastuzumab + Docetaxel
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
HER2-positive Breast Cancer
01/23
12/23
NCT06278870: Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial

Recruiting
3
312
RoW
disitamab vedotin, RC-48, Pyrotinib, trastuzumab, Pertuzumab, taxane drug
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
HER2-positive Metastatic Breast Cancer, First-line Treatment
06/31
06/31
OLIGAMI, NCT06135714: Metastasis-directed Therapy for Oligometastases of Breast Cancer

Recruiting
3
340
Japan
Systemic therapy for 12 weeks after primary registration, Radiation therapy (SBRT/conventional RT), Surgery, Same systemic therapy after secondary registration
Tokyo Medical and Dental University
Breast Cancer, Oligometastasis, Metastatic Breast Cancer
11/26
10/32
PATINA, NCT02947685 / 2017-000419-17: Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer

Hourglass Jan 2023 - Dec 2023 : From PATINA trial in combination with anti-HER2 therapy and endocrine therapy for HER2+ metastatic breast cancer
Active, not recruiting
3
496
Europe, US, RoW
palbociclib, Ibrance, trastuzumab, Herceptin, pertuzumab, Perjeta, letrozole, Femara, Anastrozole, Arimidex, Exemestane, Aromasin, Fulvestrant, Faslodex
Alliance Foundation Trials, LLC., Pfizer, German Breast Group, Fondazione Michelangelo, PrECOG, LLC., Breast Cancer Trials, Australia and New Zealand, Syneos Health, SOLTI Breast Cancer Research Group, UNICANCER
HER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast Cancer
09/24
07/26
HELEN-006, NCT04547907: A Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early Breast Cancer

Recruiting
3
688
RoW
Nab-paclitaxel+ trastuzumab+ patuzumab, nab-PHP regimen group, Docetaxel+ carboplatin+ trastuzumab + patuzumab, TCbHP regimen group
Henan Cancer Hospital
Breast Cancer,HER2-positive
12/24
12/24
KATE3, NCT04740918 / 2020-002818-41: A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)

Completed
3
96
Europe, Canada, US, RoW
Trastuzumab Emtansine, Kadcyla, T-DM1, RO5304020, Atezolizumab, Tecentriq, RO5541267, MPDL3280A, Placebo
Hoffmann-La Roche
Metastatic Breast Cancer
06/24
06/24
NCT05871918: A Multicenter, Randomized, Open, Phase III Trial of ddEC-THPvs Evaluating the Efficacy and Safety of TCHP Neoadjuvant Therapy for HER2-positive Breast Cancer

Recruiting
3
832
RoW
TCbHP VS ddEC-THP
Tianjin Medical University Cancer Institute and Hospital
HER-2 Positive Breast Cancer
12/23
12/23
PREFER, NCT05802225: Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer

Recruiting
3
374
RoW
BCD-178, pertuzumab, Perjeta
Biocad
Breast Cancer
01/24
01/26
NCT05760612: A Clinical Study on Hormone Receptor Positive HER2 Positive Breast Cancer of RCB1-2 After Neoadjuvant Treatment With Trastuzumab Combined With Parezumab

Recruiting
3
300
RoW
Trastuzumab and nelatinib, Trastuzumab and Parstuzumab
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Early-stage Breast Cancer, HER2-positive Breast Cancer, Adjuvant Treatment After Trastuzumab, RCB Classification 1-2, Neratini
02/28
11/28
NCT05429684: Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

Recruiting
3
120
RoW
Trastuzumab, herceptin；Inetetamab, Pertuzumab, Perjeta, Nab paclitaxel, Abraxane, Pyrotinib, SHR-1258, Capecitabine, T-DM1, Trastuzumab Emtansine, Everolimus, RAD001, CDK4/6 inhibitor, Palbociclib；, AI, Letrozole, Anti-PD-1 monoclonal antibody, Sintilimab
First Affiliated Hospital Xi'an Jiaotong University
HER2+ Breast Cancer
02/24
02/24
EPIK-B2, NCT04208178 / 2019-002741-37: Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation

Calendar Jan 2025 - Dec 2025: From P3 trial for HER-2 positive breast cancer
Active, not recruiting
3
19
Europe, US, RoW
Alpelisib, BYL719, Alpelisib matching Placebo, Trastuzumab, Pertuzumab
Novartis Pharmaceuticals
Advanced HER2+Breast Cancer
12/25
12/25
FAVOR, NCT04337658: Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer

Not yet recruiting
3
493
RoW
Pertuzumab, Perjeta, Trastuzumab, Herceptin, Fulvestrant, Faslodex, Capecitabine, Xeloda
Second Affiliated Hospital, School of Medicine, Zhejiang University
HER2-positive Breast Cancer
04/24
04/26
NCT04858529: Neoadjuvant TCHP Versus THP in Patients With HER2-positive Breast Cancer (neoCARHP Study)

Recruiting
3
774
RoW
investigator-selected taxane/carboplatin/trastuzumab/pertuzumab (TCHP), investigator-selected taxane/trastuzumab/pertuzumab (THP)
Guangdong Provincial People's Hospital
Neoadjuvant Therapies for HER2+ Breast Cancer
04/24
04/25
NCT05283837: A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,)

Completed
3
268
RoW
Pertuzumab (ZRC-3277), Pertuzumab (Perjeta®)
Zydus Lifesciences Limited
Metastatic Breast Cancer
09/23
09/23
ProHer, NCT05415215 / 2021-002346-33: A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer

Active, not recruiting
3
347
Europe, Canada, RoW
Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC), PHESGO®, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, Pertuzumab, Trastuzumab, and rHuPH20, RO7198574, RG6264, Pertuzumab IV, Perjeta®, RO4368451, Trastuzumab IV, Herceptin®, RO0452317, Trastuzumab Emtansine, Kadcyla®, ado-trastuzumab emtansine, T-DM1, RO5304020, Investigator's Choice of Chemotherapy, Surgery, Radiotherapy
Hoffmann-La Roche, F. Hoffmann-La Roche Ltd
Early Breast Cancer, Locally Advanced Breast Cancer, Inflammatory Breast Cancer
03/25
12/25
DETECT V, NCT02344472 / 2014-002249-22: Detect V / CHEVENDO (Chemo vs. Endo)

Active, not recruiting
3
271
Europe
pertuzumab, Perjeta®, Trastuzumab, Herceptin®, Capecitabine, Paclitaxel, Vinorelbine, Docetaxel, Exemestane, Letrozole, Anastrozole, Fulvestrant, Ribociclib, Kisqali®, nab-Paclitaxel, eribulin, leuprorelin, goserelin
Prof. Wolfgang Janni, Roche Pharma AG, Novartis Pharmaceuticals, Eisai GmbH, Celgene Corporation
Metastatic Breast Cancer
01/25
01/25
NCT06490536: The Sagittarius Trial

Not yet recruiting
3
700
NA
Oxaliplatin, Capecitabine, Folinic acid, Fluorouracil, Temozolomide, Irinotecan, Nivolumab, Ipilimumab, Trastuzumab, Pertuzumab, Panitumumab
IFOM ETS - The AIRC Institute of Molecular Oncology
Colon Cancer Stage II, Colon Cancer Stage III
03/26
09/28
NCT05474690: A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer

Withdrawn
3
456
RoW
Docetaxel + Carboplatin + Trastuzumab + Pertuzumab, TCbHP regimen group, (Epirubicin + Cyclophosphamide - Docetaxel) + (Trastuzumab + Pertuzumab), ECHP-THP regimen group
Henan Cancer Hospital
Breast Cancer, HER2-positive Breast Cancer
03/23
08/24
NCT05159193: Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer

Recruiting
3
372
RoW
pegylated liposomal doxorubicin (PLD), duomeisu, Doxorubicin Hydrochloride Liposome Injection, cyclophosphamide (C), huanlinxianan, trastuzumab (H), qutuozhudankang, pertuzumab (P), patuozhudankang, docetaxel (T), duoxitasai, carboplatin (Cb), kabo
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, CSPC Ouyi Pharmaceutical Co., Ltd.
Breast Cancer
10/24
01/28
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen Inc., Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
NCT05346224: A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer

Active, not recruiting
3
900
RoW
HLX11, Recombinant anti-HER2 domain II humanized monoclonal antibody injection, EU-Perjeta®
Shanghai Henlius Biotech
Breast Cancer, Breast Neoplasms, HER2-positive Breast Cancer
11/24
12/25
DESTINY-Breast11, NCT05113251 / 2021-000603-21: Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

Calendar Jan 2024 - Dec 2024: Data from DESTINY-Breast11 trial for HER2-positive, breast cancer
Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission for breast cancer (based on DESTINY-Breast11 trial)
Active, not recruiting
3
927
Europe, Canada, Japan, US, RoW
Trastuzumab Deruxtecan, T-DXd, Enhertu, Paclitaxel, Taxol, Onxol, Trastuzumab, Herceptin, Herzuma, Pertuzumab, Perjeta, Doxorubicin, Adriamycin, Rubex, cyclophosphamide, Neosar, Cytoxan
AstraZeneca, Daiichi Sankyo
Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer
12/24
04/27
DESTINY-Breast09, NCT04784715 / 2020-004074-21: Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer

Calendar Jan 2024 - Dec 2024: Data from DESTINY-Breast09 trial for HER2-positive, first-line metastatic breast cancer
Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission for HER2+ metastatic breast cancer (based on DESTINY-Breast09 trial)
Checkmark Data from DESTINY-Breast09 trial for HER2-positive, first-line metastatic breast cancer at ESMO 2021
Jul 2021 - Jul 2021: Data from DESTINY-Breast09 trial for HER2-positive, first-line metastatic breast cancer at ESMO 2021
Active, not recruiting
3
1157
Europe, Canada, Japan, US, RoW
Trastuzumab deruxtecan, DS-8201a; T-DXd, Placebo, Taxane, Pertuzumab, Trastuzumab
AstraZeneca, Daiichi Sankyo
Breast Cancer; HER2-positive; Metastatic
07/25
12/29
SU2C ACT3, NCT03803553: Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

Recruiting
3
400
US
FOLFIRI Protocol, FOLinic acid-Fluorouracil-IRInotecan regimen, ACTIVE SURVEILLANCE, Nivolumab Protocol, Nivolumab, Encorafenib/Binimetinib/Cetuximab Protocol, Enco/Bini/Cetux, Trastuzumab + Pertuzumab, Herceptin
Massachusetts General Hospital, Stand Up To Cancer
Metastatic Colon Cancer, Stage III Colon Cancer
12/26
12/27
NCT05720026: Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer

Recruiting
3
560
RoW
SYSA1901, pertuzumab biosimilar, Pertuzumab, Perjeta®, Trastuzumab, Herceptin®, Docetaxel, Docetaxel injection
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
HER2-positive Breast Cancer
08/25
02/26
NCT02320435 / 2014-002048-42: A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial

Active, not recruiting
3
154
Europe, Japan, RoW
Pertuzumab, RO4368451, Perjeta, Trastuzumab, Other Combination Anti-Cancer Therapies
Hoffmann-La Roche
Solid Tumor
12/25
12/25
NCT06038539: Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer

Not yet recruiting
3
382
NA
PERT-IJS plus trastuzumab, carboplatin and docetaxel, Perjeta plus trastuzumab, carboplatin and docetaxel
Biocon Biologics UK Ltd
HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
03/26
11/26
NCT05838066: Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.

Not yet recruiting
3
880
NA
KN026, HB1801, Pertuzumab, Trastuzumab, Docetaxel
Shanghai JMT-Bio Inc.
First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
07/26
12/27
APTneo, NCT03595592 / 2017-000981-31: Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer

Active, not recruiting
3
650
Europe
Trastuzumab, Herceptin, Pertuzumab, Perjeta, Carboplatin, Carboplatin Hospiria, Paclitaxel, Paclitaxel Hospiria, Doxorubicin, Doxorubicin Pfizer, Cyclophosphamide, Cyclophosphamide Sandoz, Atezolizumab, Tecentriq, Surgery
Fondazione Michelangelo, Hoffmann-La Roche
Invasive Breast Cancer
12/26
03/27
NCT05698186: Thero2-01S22 in HER2-positive Breast Cancer

Not yet recruiting
3
320
NA
Thero2-01S22, Placebo
Institut de cancérologie Strasbourg Europe
HER2-positive Breast Cancer
05/27
05/27
TRAP-2, NCT05188313: TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer

Recruiting
3
376
Europe
Trastuzumab, Pertuzumab, Paclitaxel, Carboplatin
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Esophageal Cancer, Esophageal Adenocarcinoma
07/27
02/37
ChiCTR2100048136: Trastuzumab combined with pertuzumab and sequential use of pyrotinib vs trastuzumab combined with pertuzumab for adjuvant treatment of non-pCR HER2-positive breast cancer after neoadjuvant therapy: a prospective, randomized control, stage iii clinical trial

Not yet recruiting
3
450
 
test drug for pyrotinib ;No
Shengjing Hospital of China Medical University; Shengjing Hospital of China Medical University, No
Breast cancer
 
 
NCT04973319: Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy

Not yet recruiting
3
450
RoW
Pyrotinib, Trastuzumab and pertuzumab, Trastuzumab, pertuzumab
Shengjing Hospital
Breast Cancer
08/27
08/27
SHR-A1811-307, NCT06057610: A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer

Not yet recruiting
3
864
NA
SHR-A1811 Injection, SHR-A1811 Injection ； Pertuzumab Injection, Trastuzumab Injection；Pertuzumab Injection ； Docetaxel Injection
Jiangsu HengRui Medicine Co., Ltd.
HER2-PositiveRecurrent or Metastatic Breast Cancer
10/27
10/32
NCT05883852: EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer

Recruiting
3
1406
RoW
Docetaxel, carboplatin, Trastuzumab, Pertuzumab, Epirubicin, cyclophosphamide
Fudan University
HER2 Positive Early Breast Cancer
07/31
07/31
2011-001462-17: Trial for the optimisation of risk assessment and therapy success predicition in patients with early breast cancer by the use of biomarkers in advance to therapy decission-making to personalize therapies.

Ongoing
2/3
5236
Europe
Epirubicin, Cyclophosphamide, Paclitaxel, Tamoxifen, Anastrozole, Letrozole, Exemestan, trastuzumab emtansine (T-DM1), Trastuzumab, Paclitaxel-Albumin, Gemcitabine, Carboplatin, Pertuzumab, Myocet, RO530-4020/xxx, RO4368451, Concentrate for solution for infusion, Tablet, Powder for concentrate for solution for infusion, Powder for solution for infusion, Kadcyla, Herceptin 150 mg, Abraxane, Perjeta
Westdeutsche Studiengruppe GmbH, Genomic Health , Inc., Roche Pharma AG, Celgene Corp., Amgen, TEVA GmbH, Bayer AG
Early primary breast cancer, hormone receptor positve or negative, HER2 positive or negative, any nodal status., Early diagnosed breast cancer at first occurence, with hormone receptor over-expressing tumor and any lymph node involvement (from none to any)., Diseases [C] - Cancer [C04]
 
 
PREDIX HER2, NCT02568839 / 2014-000808-10: Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer

Active, not recruiting
2/3
202
Europe
docetaxel + trastuzumab sc + pertuzumab, Herceptin SC, Perjeta, trastuzumab emtansin, Kadcyla
Thomas Hatschek, Dept. of Oncology, Karolinska University Hospital
Early-Stage Breast Carcinoma, HER-2 Positive Breast Cancer
02/19
02/29
NCT05426486: A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

Active, not recruiting
2/3
136
RoW
ARX788, Pyrotinib maleate, Trastuzumab, Pertuzumab, Docetaxel, Carboplatin
Caigang Liu, Jiangsu HengRui Medicine Co., Ltd.
HER2-positive Breast Cancer
12/25
12/28
NRG-GY026, NCT05256225: Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Recruiting
2/3
525
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Hyaluronidase-zzxf/Pertuzumab/Trastuzumab, Pertuzumab and Trastuzumab hyaluronidase, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, Pertuzumab/Trastuzumab/Hyaluronidase-zzxf, Phesgo, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, MUGA, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Quality-of-Life Assessment, Quality of Life Assessment, Trastuzumab/Hyaluronidase-oysk, Herceptin Hylecta, Trastuzumab and Hyaluronidase, Trastuzumab and Hyaluronidase-oysk, Trastuzumab and Recombinant Human Hyaluronidase PH20, Trastuzumab and rHuPH20, Trastuzumab-Hyaluronidase-oysk
National Cancer Institute (NCI), NRG Oncology
Endometrial Serous Adenocarcinoma, Uterine Corpus Carcinosarcoma
10/27
10/27
CRUKD/21/004, NCT05722886: DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol

Recruiting
2/3
825
Europe
Alectinib, Alecensa, Atezolizumab, Tecentriq, Entrectinib, Rozlytrek, Trastuzumab in combination with pertuzumab, Herceptin in combination with Perjeta, Vemurafenib in combination with cobimetinib, Zelboraf in combination with Cotellic
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy
10/29
10/29
DETERMINE, NCT05786716: Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations

Recruiting
2/3
30
Europe
Trastuzumab, Herceptin, Pertuzumab, Perjeta
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy, Colorectal Neoplasms, Urinary Bladder Neoplasm, Gallbladder Neoplasms, Salivary Gland Neoplasm, Lung Neoplasm, Pancreatic Neoplasm, Ovarian Neoplasms, Prostatic Neoplasm, Skin Neoplasm
10/29
10/29
TRIUMPH, UMIN000027887: Multicenter Phase II study to evaluate efficacy and safety of combination therapy with trastuzumab and pertuzumab in patients with HER2-positive metastatic colorectal cancer

Completed
2
50
Japan
Herceptin (trastuzumab) - Roche, Perjeta (pertuzumab) - Roche
National Cancer Center Hospital East, Japan Agency for Medical Research and Development
Colorectal cancer
 
 
CTR20222482: 302H neoadjuvant single-arm study

Recruiting
2
60
China
Cipterbin (inetetamab) - 3SBio, Perjeta (pertuzumab) - Roche, paclitaxel - Generic mfg.
Sansheng Guojian Pharmaceutical (Shanghai) Co., Ltd.
Human epidermal growth factor receptor 2 (HER2)-positive breast cancer
 
 
RC48-C026, CTR20232220: A randomized, open-label, multicenter phase II clinical study evaluating the efficacy and safety of vedicitumab versus pertuzumab with or without toripalimab in the neoadjuvant treatment of patients with HER2-positive breast cancer

Ongoing
2
80
China
Aidixi (disitamab vedotin) - Rongchang Pharma, Pfizer, Loqtorzi (toripalimab) - Shanghai Junshi Biosci, Coherus Biosci, Perjeta (pertuzumab) - Roche
Remegen Biopharmaceutical (Yantai) Co., Ltd
HER2-positive breast cancer
 
 
2013-001800-13: Neoadjuvant phase II trial combining [3 FEC 100 followed by 3 docetaxel associated with trastuzumab plus pertuzumab] or [6 docetaxel, carboplatin associated with trastuzumab plus pertuzumab] according to TOP2A status in patients with T1c operable, HER2-positive breast cancer. Identification of pathological Complete Response (pCR) predictive factors.

Not yet recruiting
2
90
Europe
Solution for infusion, Powder for solution for injection, Powder for solution for infusion, FLUOROURACILE, EPIRUBICINE, ENDOXAN, DOCETAXEL, CARBOPLATINE, HERCEPTIN, PERJETA
UNICANCER, Roche Laboratories
Untreated, operable, non-metastatic and HER2-positive breast cancer (BC), Benign breast cancer, Diseases [C] - Cancer [C04]
 
 
2014-000808-10: PREDIX HER2 - preoperative treatment of HER2 positive breast cancer

Ongoing
2
200
Europe
Herceptin, Perjeta, Kadcyla, docetaxel, Solution for injection, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Concentrate and solvent for concentrate for solution for infusion, Herceptin, Perjeta, Kadcyla
Karolinska University Hospital, Dept. of Oncology, Karolinska University Hospital
Primary breast cancer, Newly diagnosed preoperative breast cancer, Diseases [C] - Cancer [C04]
 
 
NCT01817452: A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol

Recruiting
2
220
Europe
Trastuzumab, Herceptin, Pertuzumab, Paclitaxel
West German Study Group, Roche Pharma AG
Breast Cancer
08/15
10/24
TBCRC026, NCT01937117: Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer

Active, not recruiting
2
88
US
Positron emission tomography (PET), FDG PET, PET/CT, Trastuzumab, Herceptin, Pertuzumab, Perjeta
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Translational Breast Cancer Research Consortium, Genentech, Inc.
Breast Cancer
03/18
05/25
NCT01796197: Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa

Active, not recruiting
2
23
US
Trastuzumab, Pertuzumab, Paclitaxel, Doxorubicin, Cyclophosphamide, Mastectomy, Radiation Therapy
Dana-Farber Cancer Institute
Breast Cancer
06/18
07/24
NCT02326974: T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA

Active, not recruiting
2
164
US
T-DM1, Kadcyla, Pertuzumab, Perjeta, Excision of tumor/mastectomy
Dana-Farber Cancer Institute, Genentech, Inc.
HER-2 Positive Breast Cancer, Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
06/18
01/28
2018-003275-35: Reducing the number chemotherapy cycles based on radiologic tumor response in HER2-positive breast cancer: the TRAIN-3 study (BOOG 2018-01) Verminderen van het aantal kuren chemotherapie op geleide van de tumor response op beeldvorming bij HER2-positieve borstkanker: de TRAIN-3 studie

Ongoing
2
462
Europe
Herceptin, Carboplatin Sandoz, TAxol, Perjeta, na, Concentrate for solution for injection/infusion, Concentrate for solution for infusion, Herceptin, Carboplatine Sandoz, Taxol, Perjeta
BOOG Study Center, Roche
HER2-positive, stage II/III breast cancer, breast cancer, Diseases [C] - Cancer [C04]
 
 
2019-002181-12: OPTIMAL THERAPY FOR HER2 POSITIVE METASTATIC BREAST CANCER PATIENTS TERAPIA OTTIMALE PER LE PAZIENTI AFFETTE DA TUMORE DELLA MAMMELLA MESTASTATICO HER2 POSITIVO

Not yet recruiting
2
101
Europe
KADCYLA, Capecitabina, TYVERB, [Trastuzumab emtansine], [Capecitabina], [LAPATINIB], Powder and solvent for solution for infusion, Film-coated tablet, KADCYLA, TYVERB - 250 MG COMPRESSA RIVESTITA CON FILM - USO ORALE - FLACONE (HDPE) 70 COMPRESSE
ISTITUTI FISIOTERAPICI OSPITALIERI, Ministero della Salute - Ricerca Finalizzata GR 2018-12367431
HER2 POSITIVE METASTATIC BREAST CANCER CARCINOMA MAMMARIO METASTATICO HER2 POSITIVO, HER2 POSITIVE METASTATIC BREAST CANCER CARCINOMA MAMMARIO METASTATICO HER2 POSITIVO, Diseases [C] - Cancer [C04]
 
 
NeoTOP, NCT02339532: Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status

Active, not recruiting
2
86
Europe
FEC100, Docetaxel, Trastuzumab, Pertuzumab, Carboplatin
UNICANCER
Breast Cancer
10/19
06/24
2019-004771-40: ProTargetA Danish Nationwide Clinical Trial on Targeted Anti-Cancer Treatment based on Genomic Profiling

Not yet recruiting
2
300
Europe
Zejula, Capsule, hard, Concentrate and solvent for solution for infusion, Tablet, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Alcensa, Tecentriq, Cotellic, Zelboraf, Herceptin, Perjeta, Kadcyla, Erivedge, Bavencio, Inlyta, Zejula, pemazyre, Retsevmo
Rigshospitalet, Roche, Pfizer
Eligible patients will have an advanced malignant disease for which standard treatment options are no longer available or feasible and acceptable performance status and organ function. Patienter med fremskreden og/eller metastatisk solid tumor, som har oplevet progression under standardbehandling, eller som er intolerante over for standardbehandling, Patients with advanced cancer without curative therapeutic options Patienter med fremskreden kræft uden mulighed for kurativ behandling, Diseases [C] - Cancer [C04]
 
 
PETREMAC, NCT02624973: PErsonalized TREatment of High-risk MAmmary Cancer - the Trial

Active, not recruiting
2
200
Europe
Neoadjuvant tamoxifen + goserelin (premenopausal women), Neoadjuvant letrozole (postmenopausal women), Neoadjuvant endocrine therapy + palbociclib (if lack of response to endocrine therapy alone), Neoadjuvant docetaxel + cyclophosphamide, Neoadjuvant docetaxel, Neoadjuvant docetaxel + trastuzumab + pertuzumab, Neoadjuvant docetaxel + cyclophosphamide + trastuzumab + pertuzumab, Neoadjuvant olaparib, Neoadjuvant cyclophosphamide (after 10 weeks of olaparib alone), Breast conserving surgery or mastectomy + SNB/axillary dissection, Postoperative radiotherapy breast/chest wall + regional lymph nodes, Adjuvant trastuzumab, Adjuvant letrozole (postmenopausal women), Adjuvant tamoxifen + goserelin (premenopausal women), Adjuvant palbociclib (if palbociclib given neoadjuvant), Adjuvant Epirubicin+ Cyclophosphamide
Haukeland University Hospital, Helse Vest, Pfizer, AstraZeneca
Breast Cancer
06/20
06/30
NCI-2016-00570, NCT02827877: Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer

Active, not recruiting
2
18
US
Copper Cu 64-DOTA-Trastuzumab, 64Cu-DOTA-Trastuzumab, Laboratory Biomarker Analysis, Pertuzumab, 2C4, 2C4 Antibody, MoAb 2C4, Monoclonal Antibody 2C4, Perjeta, rhuMAb2C4, RO4368451, Positron Emission Tomography, PET Scan, Therapeutic Conventional Surgery, Trastuzumab, ABP 980, Anti-c-ERB-2, Anti-c-erbB2 Monoclonal Antibody, Anti-ERB-2, Anti-erbB-2, Anti-erbB2 Monoclonal Antibody, Anti-HER2/c-erbB2 Monoclonal Antibody, Anti-p185-HER2, c-erb-2 Monoclonal Antibody, HER2 Monoclonal Antibody, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, MoAb HER2, Monoclonal Antibody c-erb-2, Monoclonal Antibody HER2, PF-05280014, rhuMAb HER2, RO0452317, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar PF-05280014
City of Hope Medical Center, National Cancer Institute (NCI)
HER2 Positive Breast Carcinoma, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
07/20
12/24
PH002-TP-II, NCT03272477 / 2016-005157-21: Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients

Completed
2
257
Europe
Perjeta Injectable Product, Pertuzumab, Herceptin, Trastuzumab, Tamoxifen, Paclitaxel, Epirubicin, Cyclophosphamide, Anastrozole, Letrozole, Exemestane, Leuprorelin acetate, Goserelin, Leuporelin acetate, Biopsy, Surgery
Palleos Healthcare GmbH, Roche Pharma AG, WSG WOMEN´S HEALTHCARE STUDY GROUP, Cankado GmbH
Breast Neoplasms
07/20
03/24
NCT01730833: Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer

Active, not recruiting
2
63
US
pertuzumab, 2C4 antibody, monoclonal antibody 2C4, Perjeta, rhuMAb-2C4, trastuzumab, anti-c-erB-2, Herceptin, MOAB HER2, paclitaxel albumin-stabilized nanoparticle formulation, ABI-007, nab paclitaxel, nab-paclitaxel, nanoparticle albumin-bound paclitaxel, laboratory biomarker analysis
City of Hope Medical Center, National Cancer Institute (NCI)
HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Breast Adenocarcinoma, Inflammatory Breast Carcinoma
01/21
12/24
2020-003395-41: Ex vivo drug sensitivity in metastatic colorectal cancer

Not yet recruiting
2
45
Europe
Alectinib, Crizotinib, Dasatinib, Everolimus, Gemcitabine, Idelalisib, Larotrectinib, Methotrexate, Palbociclib, Panobinostat, Pembrolizumab, Pertuzumab, Trastuzumab, Talazoparib, Venetoclax, Cetuximab, Encorafinib, Capsule, hard, Film-coated tablet, Tablet, Infusion, Injection, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Alecensa, Xalkori, Sprycel, Afinitor, Gemcitabine Accord, Zydelig, Vitrakvi, Methotrexat Accord, Ibrance, Farydak, Keytruda, Perjeta, Herceptin, Talzenna, Venclyxto, Erbitux, Braftovi
Oslo University Hospital, Oslo University Hospital
Metastatic Colorectal Cancer, Metastatic Colorectal Cancer, Diseases [C] - Cancer [C04]
 
 
R2D2, NCT03845270: Her2-positive Lung Cancer Treated With Dedicated Drug

Completed
2
46
Europe
pertuzumab + trastuzumab + docetaxel
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer Stage III, HER2 Gene Mutation
02/21
12/23
PRETTY, NCT04255056: Pyrotinib in Breast Cancer Patients With Poor Response to the Neoadjuvant Treatment of Trastuzumab and Pertuzumab

Not yet recruiting
2
27
RoW
Pyrotinib, epirubicin, cyclophosphamide
Sun Yat-sen University
Breast Cancer
02/21
02/25
IMMUN-HER, NCT03144947 / 2016-000435-41: Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Trastuzumab in HER2+ Breast Cancer Patients

Active, not recruiting
2
65
Europe
Trastuzumab IV, Herceptin-150 mg, Trastuzumab SC, Herceptin-600 mg/5 mL, Pertuzumab, PerJeta 420 mg, Docetaxel, Docetaxel 20 MG/ML
Gruppo Oncologico Italiano di Ricerca Clinica, University Hospital of Parma: Department of Biomedical, Biotechnological and Translational Sciences, Pathological Anatomy and Histology Unit, University Hospital of Parma:Laboratory of Viral Immunopathology, Unit of Infectious Diseases and Hepatology, University Hospital of Parma:Statistica medica ed epidemiologia clinica-UO Ricerca e Innovazione, Clirest s.r.l., Mipharm SpA, Arithmos srl, Temas srl
Cancer, Breast
03/21
11/21
ChiCTR1900028433: A Phase II single-arm clinical study of neoadjuvant treatment with pegylated liposomal doxorubicin (PLD) plus cyclophosphamide combined with trastuzumab and Pertuzumab in HER-2 positive breast cancer

Completed
2
78
 
pegylated liposomal doxorubicin (PLD) plus cyclophosphamide combined with trastuzumab and pertuzumab followed by taxanes and trastuzumab and pertuzumab
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University; Sun Yat-Sen Memorial HospitalOFSun Yat-Sen University, CSPC Ouyi Pharmaceutical Co., Ltd.
breast cancer
 
 
2019-003192-18: Phase II clinical trial with early efficacy testing and adaptive extension for rare malignant tumors

Not yet recruiting
2
175
Europe
Alectinib, Tecentriq, Vemurafenib, Cobimetinib, Ipatasertib, Herceptin, Perjeta, Inavolisib, 7113755, Capsule, hard, Infusion, Film-coated tablet, Powder for infusion, Concentrate for solution for infusion, Tecentriq, Herceptin, Perjeta
German Cancer Research Center, German Cancer Research Center, Roche Pharma AG
Metastatic or locally advanced malignancies, Previously Treated Advanced tumours, Diseases [C] - Cancer [C04]
 
 
Neo-peaks, UMIN000014649: A randomized, multicenter, phase II trial comparing neo-adjuvant therapy using pertuzumab and trastuzumab emtansine based on the dual HER2 blockade in patients with operable HER2-positive primary breast cancer( study)

Completed
2
200
Japan
tamoxifen - Generic mfg., letrozole - Generic mfg., 5-fluorouracil - Generic mfg., epirubicin - Generic mfg., cyclophosphamide - Generic mfg., Perjeta (pertuzumab) - Roche, docetaxel - Generic mfg., carboplatin - Generic mfg., Herceptin (trastuzumab) - Roche, Kadcyla (ado-trastuzumab emtansine) - Roche
Japan Breast Cancer Research Group(JBCRG), Chugai Pharmaceutical CO.,LTD
operable HER2-positive primary breast cancer
 
 
2018-004457-24: PREDIX II HER2 - improving preoperative treatment of HER2 amplified breast cancer

Not yet recruiting
2
190
Europe
Herceptin, Tecentriq, Kadcyla, Docetaxel, Carboplatin, Epirubicin, Cyclophosphamide, Pertuzumab, Paklitaxel, Solution for injection, Solution for infusion, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Powder for solution for injection/infusion, Herceptin, Tecentriq, Kadcyla
Karolinska University Hospital, Karolinska University Hospital
Primary breast cancer, Newly diagnosed HER2 amplified breast cancer, Diseases [C] - Cancer [C04]
 
 
2020-005276-35: ARTesunate in combInation with standard-of-care T-DM1 as Second-line Treatment in patients with advanced HER2-positive breast cancer progressIng on trastuzumab-pertuzumab Chemotherapy: the ARTISTIC study Artesunato in combinazione con T-DM1 come seconda linea di trattamento in pazienti con tumore mammario HER2-positivo avanzato in progressione a biochemioterapia contenente trastuzumab-pertuzumab: lo studio ARTISTIC

Not yet recruiting
2
25
Europe
Co-arinate, [Artestunato], Tablet, Co-Arinate
FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI", Roche S.p.A.
patient PFS in metastatic HER2+ breast cancer undergoing tumor progression during first-line taxane-trastuzumab-pertuzumab biochemotherapy or trastuzumab-pertuzumab maintenance, and candidate to receive second-line T-DM1 pazienti con tumore mammario HER2+ in fase avanzata e candidati a trattamento di seconda linea con T-DM1 dopo progressione a chemioterapia di prima linea contenente Trastuzumab-Pertuzumab o terapia di mantenimento con Trastuzumab-Pertuzumab., metastatic HER2+ breast cancer tumore mammario HER2+, Diseases [C] - Cancer [C04]
 
 
2020-005735-79: - Traitement par Tucatinib associé au Pertuzumab et Trastuzumab chez des patients atteints d'un cancer du sein métastatique HER2-positif après traitement local de la progression cérébrale isolée

Not yet recruiting
2
55
Europe
Pertuzumab, trastuzumab, tucatinib, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Film-coated tablet, Perjeta, Herceptin
UNICANCER, Seagen Inc.
HER2-positive metastatic breast cancer with isolated brain progression (defined as new or progressive brain metastases with stable or responding systemic disease) after complete local treatment., HER2-positive metastatic breast cancer with isolated brain progression after complete local treatment., Diseases [C] - Cancer [C04]
 
 
2018-003996-37: Neoadjuvant therapy with Pembrolizumab in combination with anti-HER2-blockade with trastuzumab and pertuzumab in early breast cancer patients with HER2+ and hormonal receptor positive or negative early breast cancer. Neoadjuvante Therapie mit Pembrolizumab in Kombination mit einer anti-HER2 Blockade mit Trastuzumab und Pertuzumab bei Patientinnen im Frühstadium von Brustkrebs mit HER+ und Hormonrezeptor positiven oder negativen Brustkrebs.

Not yet recruiting
2
46
Europe
Pembrolizumab, Pertuzumab, Trazimera, MK-3475, RO4368451, Solution for infusion, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, KEYTRUDA, Perjeta, Trazimera
Westdeutsche Studiengruppe GmbH (WSG), MSD SHARP & DOHME GmbH, NanoString Technologies, Inc.
HER 2+/HR+ and HR- early breast cancer HER 2+/HR+ and HR- früher Brustkrebs, Breast Cancer Brustkrebs, Diseases [C] - Cancer [C04]
 
 
HERMET, NCT03238495: Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer

Recruiting
2
100
US
Taxotere, Carboplatin, Herceptin + Pertuzumab, Metformin
Qamar Khan
HER2-positive Breast Cancer
06/22
06/23
2021-002323-38: Neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab with or without inavolisib Neoadjuvante endokrine Therapie in Kombination mit Trastuzumab, Pertuzumab mit oder ohne Inavolisib

Not yet recruiting
2
170
Europe
inavolisib (GDC-0077), Phesgo, RO7113755, RO7198574, Film-coated tablet, Solution for injection in vial, Phesgo
German Breast Group, F. Hoffmann-La Roche Ltd
Patients with early breast cancer Patienten mit primärem Brustkrebs, Patients with early breast cancer Patienten mit primärem Brustkrebs, Diseases [C] - Cancer [C04]
 
 
SWOG S1613, NCT03365882: S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

Active, not recruiting
2
240
US
Cetuximab, Chimeric Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225, Chimeric Monoclonal Antibody C225, Erbitux, IMC-C225, Irinotecan Hydrochloride, Campto, Camptosar, Camptothecin 11, Camptothecin-11, CPT 11, CPT-11, Irinomedac, U-101440E, Laboratory Biomarker Analysis, Pertuzumab, 2C4, 2C4 Antibody, MoAb 2C4, Monoclonal Antibody 2C4, Perjeta, rhuMAb2C4, RO4368451, Trastuzumab, ABP 980, Anti-c-ERB-2, Anti-c-erbB2 Monoclonal Antibody, Anti-ERB-2, Anti-erbB-2, Anti-erbB2 Monoclonal Antibody, Anti-HER2/c-erbB2 Monoclonal Antibody, Anti-p185-HER2, c-erb-2 Monoclonal Antibody, HER2 Monoclonal Antibody, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, MoAb HER2, Monoclonal Antibody c-erb-2, Monoclonal Antibody HER2, PF-05280014, rhuMAb HER2, RO0452317, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar PF-05280014, HER-2 testing
SWOG Cancer Research Network, National Cancer Institute (NCI)
Colon Adenocarcinoma, ERBB2 Gene Amplification, Rectal Adenocarcinoma, Recurrent Colon Carcinoma, Recurrent Rectal Carcinoma, Stage III Colon Cancer AJCC v7, Stage III Rectal Cancer AJCC v7, Stage IIIA Colon Cancer AJCC v7, Stage IIIA Rectal Cancer AJCC v7, Stage IIIB Colon Cancer AJCC v7, Stage IIIB Rectal Cancer AJCC v7, Stage IIIC Colon Cancer AJCC v7, Stage IIIC Rectal Cancer AJCC v7, Stage IV Colon Cancer AJCC v7, Stage IV Rectal Cancer AJCC v7, Stage IVA Colon Cancer AJCC v7, Stage IVA Rectal Cancer AJCC v7, Stage IVB Colon Cancer AJCC v7, Stage IVB Rectal Cancer AJCC v7
11/22
11/24
TRAIN-3, NCT03820063: Image-guided De-escalation of Neo-adjuvant Chemotherapy in HER2-positive Breast Cancer: the Study

Active, not recruiting
2
462
Europe
PTC-Pz
Borstkanker Onderzoek Groep, Roche Pharma AG, BOOG Study Center
Breast Cancer
11/22
05/32
2019-002364-27: A study to assess atezolizumab in combination with dual HER2 blockade plus epirubicin as neoadjuvant therapy for HER2-positive early breast cancer

Not yet recruiting
2
58
Europe
Atezolizumab, Pertuzumab, Herceptin, RO5541267/F03, RO4368451, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Tecentriq, Perjeta, Herceptin
ABCSG (Austrian Breast & Colorectal Cancer Study Group), Roche Austria GmbH
HER2-positive early breast cancer, Early diagnosed with breast cancer that is HER2-positive, Diseases [C] - Cancer [C04]
 
 
NCT04246502: Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer

Not yet recruiting
2
200
NA
Capecitabine and Pyrotinib, Capecitabine,Trastuzumab, and Pertuzumab
Shandong Cancer Hospital and Institute
Metastatic Breast Cancer
12/22
12/24
 

Download Options